166 related articles for article (PubMed ID: 17341023)
21. Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human alpha-thrombin.
Jiang H; Chen K; Tang Y; Chen J; Li Q; Wang Q; Ji R
J Med Chem; 1997 Sep; 40(19):3085-90. PubMed ID: 9301672
[TBL] [Abstract][Full Text] [Related]
22. Enzyme binding selectivity prediction: alpha-thrombin vs trypsin inhibition.
Mlinsek G; Novic M; Kotnik M; Solmajer T
J Chem Inf Comput Sci; 2004; 44(5):1872-82. PubMed ID: 15446847
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of human alpha-thrombin by a phosphonate tripeptide proceeds via a metastable pentacoordinated phosphorus intermediate.
Skordalakes E; Dodson GG; Green DS; Goodwin CA; Scully MF; Hudson HR; Kakkar VV; Deadman JJ
J Mol Biol; 2001 Aug; 311(3):549-55. PubMed ID: 11493008
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin.
Féthière J; Tsuda Y; Coulombe R; Konishi Y; Cygler M
Protein Sci; 1996 Jun; 5(6):1174-83. PubMed ID: 8762149
[TBL] [Abstract][Full Text] [Related]
25. From natural to synthetic multisite thrombin inhibitors.
Lombardi A; De Simone G; Galdiero S; Staiano N; Nastri F; Pavone V
Biopolymers; 1999; 51(1):19-39. PubMed ID: 10380350
[TBL] [Abstract][Full Text] [Related]
26. The methyl group of N(alpha)(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage.
Friedrich R; Steinmetzer T; Huber R; Stürzebecher J; Bode W
J Mol Biol; 2002 Mar; 316(4):869-74. PubMed ID: 11884127
[TBL] [Abstract][Full Text] [Related]
27. High resolution crystal structures of free thrombin in the presence of K(+) reveal the molecular basis of monovalent cation selectivity and an inactive slow form.
Carrell CJ; Bush LA; Mathews FS; Di Cera E
Biophys Chem; 2006 Jun; 121(3):177-84. PubMed ID: 16487650
[TBL] [Abstract][Full Text] [Related]
28. Novel non-covalent thrombin inhibitors incorporating P(1) 4,5,6,7-tetrahydrobenzothiazole arginine side chain mimetics.
Marinko P; Krbavcic A; Mlinsek G; Solmajer T; Bakija AT; Stegnar M; Stojan J; Kikelj D
Eur J Med Chem; 2004 Mar; 39(3):257-65. PubMed ID: 15051174
[TBL] [Abstract][Full Text] [Related]
29. Caspase-3 binds diverse P4 residues in peptides as revealed by crystallography and structural modeling.
Fang B; Fu G; Agniswamy J; Harrison RW; Weber IT
Apoptosis; 2009 May; 14(5):741-52. PubMed ID: 19283487
[TBL] [Abstract][Full Text] [Related]
30. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
Tucker TJ; Lumma WC; Mulichak AM; Chen Z; Naylor-Olsen AM; Lewis SD; Lucas R; Freidinger RM; Kuo LC
J Med Chem; 1997 Mar; 40(6):830-2. PubMed ID: 9083470
[No Abstract] [Full Text] [Related]
31. Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data.
Brandstetter H; Engh RA; Von Roedern EG; Moroder L; Huber R; Bode W; Grams F
Protein Sci; 1998 Jun; 7(6):1303-9. PubMed ID: 9655333
[TBL] [Abstract][Full Text] [Related]
32. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.
Bone R; Lu T; Illig CR; Soll RM; Spurlino JC
J Med Chem; 1998 Jun; 41(12):2068-75. PubMed ID: 9622548
[TBL] [Abstract][Full Text] [Related]
33. High-resolution neutron protein crystallography with radically small crystal volumes: application of perdeuteration to human aldose reductase.
Hazemann I; Dauvergne MT; Blakeley MP; Meilleur F; Haertlein M; Van Dorsselaer A; Mitschler A; Myles DA; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2005 Oct; 61(Pt 10):1413-7. PubMed ID: 16204895
[TBL] [Abstract][Full Text] [Related]
34. More than a simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the s1 pocket of thrombin.
Baum B; Mohamed M; Zayed M; Gerlach C; Heine A; Hangauer D; Klebe G
J Mol Biol; 2009 Jul; 390(1):56-69. PubMed ID: 19409395
[TBL] [Abstract][Full Text] [Related]
35. Compounds binding to the S2-S3 pockets of thrombin.
Nilsson M; Hämäläinen M; Ivarsson M; Gottfries J; Xue Y; Hansson S; Isaksson R; Fex T
J Med Chem; 2009 May; 52(9):2708-15. PubMed ID: 19371038
[TBL] [Abstract][Full Text] [Related]
36. A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions.
Olsen J; Seiler P; Wagner B; Fischer H; Tschopp T; Obst-Sander U; Banner DW; Kansy M; Müller K; Diederich F
Org Biomol Chem; 2004 May; 2(9):1339-52. PubMed ID: 15105924
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors.
Parlow JJ; Stevens AM; Stegeman RA; Stallings WC; Kurumbail RG; South MS
J Med Chem; 2003 Sep; 46(20):4297-312. PubMed ID: 13678408
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution.
Chen Z; Li Y; Mulichak AM; Lewis SD; Shafer JA
Arch Biochem Biophys; 1995 Sep; 322(1):198-203. PubMed ID: 7574675
[TBL] [Abstract][Full Text] [Related]
39. Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: a kinetic, thermodynamic and X-ray crystallographic study.
De Simone G; Balliano G; Milla P; Gallina C; Giordano C; Tarricone C; Rizzi M; Bolognesi M; Ascenzi P
J Mol Biol; 1997 Jun; 269(4):558-69. PubMed ID: 9217260
[TBL] [Abstract][Full Text] [Related]
40. From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs.
Hanessian S; Therrien E; Zhang J; Otterlo Wv; Xue Y; Gustafsson D; Nilsson I; Fjellström O
Bioorg Med Chem Lett; 2009 Sep; 19(18):5429-32. PubMed ID: 19674897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
